Search Within

Heiko Schoder

  1. "Michael Morris"
Formats
  1. Meeting Abstract (14)
  2. Journal Article (10)
  3. Book Section (1)
Groups
  1. Department of Medicine (25)
  2. Genitourinary Oncology Service (25)
  3. Molecular Imaging and Therapy Service (25)
  4. Radiology, Department of (25)
  5. Solid Tumor Oncology Division (25)
  6. GSK Faculty (18)

More Groups

People
  1. Michael Morris (25)
  2. Howard Scher (18)
  3. Steven Larson (16)
  4. Josef Fox (15)
  5. John Humm (11)
  6. Karen Autio (7)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2023 (2)
  4. 2022 (1)
  5. 2021 (2)
  6. 2020 (1)

More Years

Publications
  1. Journal of Clinical Oncology (12)
  2. Journal of Nuclear Medicine (3)
  3. Acta Oncologica (1)
  4. Annals of Oncology (1)
  5. Cancer Research (1)
  6. Clinical Cancer Research (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (12)
  2. Society of Nuclear Medicine (3)
  3. American Association for Cancer Research (2)
  4. Springer (2)
  5. American Medical Association (1)
  6. Elsevier B.V. (1)

More Publishers

Results (25)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pathologic correlation of 18F-16 beta-fluoro-5 alpha-dihydrotestosterone (FDHT) and FDG PET in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Feldman, J. L.; Fox, J. J.; Martinez, D. F.; Autio, K. A.; Durack, J. C.; Humm, J.; Schoder, H.; Gavane, S. C.; Curtis, K. R.; Balakirsky, S. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Evaluating 18F-16 beta-fluoro-5 alpha-dihydrotestosterone (FDHT) and FDG PET as prognostic biomarkers for patients (pts) treated with abiraterone acetate (AA)
    Meeting Abstract

    Feldman, J. L.; Fox, J. J.; Autio, K. A.; Gavane, S. C.; Heller, G.; Schoder, H.; Humm, J.; Martinez, D. F.; Slovin, S. F.; Scher, H. I.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Post-treatment alterations in 18F-dihydrotestosterone (FDHT) and FDG PET/CT in metastatic castration-resistant prostate cancer (mCRPC) treated with cabozantinib
    Meeting Abstract

    Fox, J. J.; Haupt, E. C.; Humm, J.; Autio, K. A.; Rathkopf, D. E.; Vargas, H. A.; Schöder, H.; Hricak, H.; Larson, S. M.; Scher, H. I.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Evaluating 18F-16B-fluoro-5α-dihydrotestosterone (FDHT) and FDG-PET as a measure of disease progression in metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Autio, K. A.; Fox, J. J.; Schneider, C. W.; Schöder, H.; Humm, J.; Rathkopf, D. E.; Slovin, S. F.; Danila, D. C.; Haupt, E. C.; Larson, S. M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • 18F-16 beta-fluoro-5 alpha-dihydrotestosterone (FDHT) PET as a prognostic biomarker for survival in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Autio, K. A.; Fox, J. J.; Jia, X.; Heller, G.; Schoder, H.; Humm, J.; Haupt, E. C.; Schneider, C.; Scher, H. I.; Larson, S. M.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Comparison of PSA, FDG-PET, and Prostate Cancer Working Group 2 (PCWG2) criteria to interpret apparent progression on first post-treatment bone scan
    Meeting Abstract

    Autio, K. A.; Fox, J. J.; Haupt, E. C.; Schoder, H.; Scher, H. I.; Larson, S. M.; Morris, M. J.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Bone scan index: A quantitative treatment response biomarker for castration-resistant metastatic prostate cancer
    Journal Article

    Dennis, E. R.; Jia, X.; Mezheritskiy, I. S.; Stephenson, R. D.; Schoder, H.; Fox, J. J.; Heller, G.; Scher, H. I.; Larson, S. M.; Morris, M. J.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • The PCCTC imaging data capture toolset: An analysis of its impact on prostate cancer clinical trial accuracy and workload
    Meeting Abstract

    Dennis, E. R.; Fox, J. J.; Larson, S. M.; Farrelly, J. S.; Schwartz, L. H.; Schöder, H.; Haupt, E. C.; Borwick, L. S.; Scher, H. I.; Morris, M. J.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Fluorodeoxyglucose (FDG) positron emission tomography (PET) as an indicator of disease progression for patients with castration-resistant metastatic prostate cancer (CRMPC)
    Meeting Abstract

    Baklajian, A.; Dennis, E. R.; Buddle, J. R.; Fox, J. J.; Schoder, H.; Morris, M. J.; Larson, S. M.; Scher, H. I.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • The Prostate Cancer Clinical Trials Consortium (PCCTC) bone scan data capture tool for clinical trials using Prostate Cancer Working Group 2 (PCWG2) criteria: Effect on data accuracy and workload
    Meeting Abstract

    Morris, M. J.; Farrelly, J. S.; Fox, J. J.; Dennis, E. R.; Schwartz, L. H.; Schoder, H.; Haupt, E. C.; Borwick, L. S.; Larson, S. M.; Scher, H. I.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save